BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis
(NASDAQ: ISO), the leader in functional single-cell proteomics,
today announced the appointment of two new leadership positions at
the company. Michelle Reid, Ph.D.
joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of
Operations. With these appointments, IsoPlexis continues to
strengthen its operations and product support teams, providing high
need proteomic products with highly customer centric support.
![(PRNewsfoto/IsoPlexis) (PRNewsfoto/IsoPlexis)](https://mma.prnewswire.com/media/886890/isoplexis__Logo.jpg)
Ms. Reid comes to IsoPlexis with over 20 years of experience
leading and developing customer experience teams for regulated and
non-regulated molecular products and a Ph.D in Molecular Biology
from LaTrobe University in Australia. Previously, she was the Senior
Director of Customer Service and Support at PGDx, where she built
the customer experience teams from the ground up. She was also a
key player in the growth and development of the customer support
team at QIAGEN, a global leader in sample and assay technologies
for molecular diagnostics and life sciences research.
Before joining IsoPlexis, Mr. Catalano spent 11 years as Senior
Director of Operations at PerkinElmer, Inc., a Massachusetts-based supplier of unique
solutions to the diagnostics, life sciences, food, and applied
markets. He also served as Senior Director of Manufacturing
Operations at VisEn Medical Inc. from 2001 until its acquisition by
PerkinElmer in 2010. Mr. Catalano has a background as a scientist
and manufacturing engineer and an M.S. in Chemistry from
Brandeis University.
"We are excited to have Michelle and Anthony join our team at
IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "As we enter
the next phase of our growth, our new hires will help us continue
to drive operational excellence and deliver important innovations
to the market. Their depth of experience will help us continue our
global expansion and customer focus worldwide."
About IsoPlexis
IsoPlexis is leading a new era of functional proteomics. By
identifying our most proteomically active single cells (or
"superhero cells") for the first time, IsoPlexis enables
researchers to connect more directly to in vivo biology and develop
more precise and personalized therapies. IsoPlexis has been named
Top Innovation or Design by The Scientist Magazine, Fierce, BIG
Innovation, Red Dot and multiple others. The IsoPlexis platform is
used globally by researchers, including those at the top 15 global
pharmaceutical companies and at the majority of leading U.S.
comprehensive cancer centers.
Cautionary Note Regarding Forward Looking Statements
Certain statements in this press release are forward-looking
statements that are subject to risks and uncertainties that could
cause results to be materially different than expectations.
Important factors that could cause actual results to differ
materially include: the rate of adoption of the Company's
technology by its customers and potential customers as well as the
risk factors set forth in the Risk Factors section of the Company's
prospectus filed with the SEC. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, IsoPlexis
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
Related Links
www.isoplexis.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/isoplexis-bolsters-its-global-operational-and-product-support-leadership-301422850.html
SOURCE IsoPlexis